Apellis Pharmaceuticals, Inc. (26)

Browse by Contract Category

Contracts

Underwriting Agreement, dated March 23, 2022, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C (Filed With SEC on March 25, 2022)
Offer Letter, dated as of November 16, 2018, by and between the Registrant and Adam Townsend (Filed With SEC on February 28, 2022)
Summary of Non-Employee Director Compensation Program (Filed With SEC on February 28, 2022)
Amended and Restated Commercial Supply Agreement, dated March 10, 2021, by and between the Registrant, Apellis Switzerland GmbH and NOF Corporation (Filed With SEC on April 28, 2021)
Fourth Amendment to Lease, dated November 13, 2020, by and between Registrant and NWALP PHOP Property Owner LLC (Filed With SEC on February 25, 2021)
Offer Letter, dated as of April 20, 2020, by and between the Registrant and Nur Nicholson (Filed With SEC on February 28, 2022)
Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on February 28, 2022)
Open Market Sale AgreementSM, dated as of January 20, 2022, by and between Apellis Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on January 20, 2022)
Underwriting Agreement, dated November 15, 2021, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C (Filed With SEC on November 17, 2021)
Form of Exchange Agreement (Filed With SEC on July 8, 2021)
Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on February 25, 2021)
Form of Exchange Agreement (Filed With SEC on January 7, 2021)
Amendment No. 1 to 2017 Employee Stock Purchase Plan (Filed With SEC on November 2, 2020)
Form of Capped Call Transaction Confirmation (Filed With SEC on May 7, 2020)
Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on February 27, 2020)
Underwriting Agreement, dated January 8, 2020, by and among the Company and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group L.L.C (Filed With SEC on January 9, 2020)
Third Amendment to Lease, dated September 25, 2019, by and between Registrant and NWALP PHOP Property Owner LLC (Filed With SEC on November 5, 2019)
Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan (Filed With SEC on October 7, 2019)
Indenture (including form of Note), dated as of September 16, 2019, by and between Apellis Pharmaceuticals, Inc and U.S. Bank National Association, as trustee (Filed With SEC on September 16, 2019)
Form of Capped Call Transaction Confirmation (Filed With SEC on September 16, 2019)
Second Amendment to Lease, dated June 5, 2019, by and between Registrant and NWALP PHOP Property Owner LLC (Filed With SEC on July 31, 2019)
Amendment, dated as of June 7, 2019, to the Development Funding Agreement, dated as of February 28, 2019 by and between the Registrant and SFJ Pharmaceuticals XI, L.P (Filed With SEC on July 31, 2019)
Offer Letter, dated as of April 13, 2018, by and between the Registrant and Lukas Scheibler (Filed With SEC on May 7, 2019)
Standard Office Lease, dated as of March 29, 2019, by and between the Registrant and Geary-Market Investment Company, Ltd (Filed With SEC on May 7, 2019)
Development Funding Agreement, dated as of February 28, 2019 by and between the Registrant and SFJ Pharmaceuticals XI, L.P (Filed With SEC on May 7, 2019)
Underwriting Agreement, dated March 6, 2019, by and among the Company and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Cowen and Company, LLC (Filed With SEC on March 7, 2019)